Session VI: Mobile Technologies in Perspective

TAKE ACTION: Visit https://www.ctti-clinicaltrials.org/projects/mobile-technologies to access the CTTI’s Mobile Technologies recommendations and resources

SESSION PANELISTS

Francesca Cerreta, MSc, MPharm
Senior Scientific Officer, EMA
Ms. Cerreta focuses on the establishment and implementation of the EMA geriatric medicines initiative. Prior, at EMA, she covered different roles, as Scientific Administrator in the area of Quality of Medicines with a focus on innovative technologies, in Scientific Advice, where she coordinated the establishment of the parallel scientific advice procedure, and in the CNS section of the Safety and Efficacy of Medicines. She also worked as a research scientist at the CNRS laboratories in Caen (France) and subsequently for Merck in the field of molecular biology and for Eli Lilly in clinical research. Ms. Cerreta qualified from the Universita’ degli Studi di Firenze (Italy) as a pharmaceutical chemist in 1992, and as a pharmacist in 2003.

Ray Dorsey, MD, MBA
Professor of Neurology and Director, Center for Health and Technology, University of Rochester Medical Center
Dr. Dorsey is a Professor of Neurology and Director of the Center for Human Experimental Therapeutics and Center for Health and Technology at the University of Rochester Medical Center. Dr. Dorsey is helping investigate new treatments for movement disorders and improve the way care is delivered for individuals with Parkinson’s disease and other neurological disorders. Using simple web-based video conferencing, he and his colleagues are seeking to provide care to anyone anywhere. Dr. Dorsey previously directed the movement disorders division and neurology telemedicine at Johns Hopkins and worked as a consultant for McKinsey & Company. He completed his undergraduate studies at Stanford University, medical school at the University of Pennsylvania, and business school at the Wharton School. Dr. Dorsey’s research has been published in the leading medical, neurology, and economic journals and has been featured on National Public Radio, in The New York Times, and in The Wall Street Journal. Dr. Dorsey is a team lead on the CTTI MCT Mobile Technologies project.

Pat Furlong, BSN
Founding President and CEO, Parent Project Muscular Dystrophy (PPMD)
Ms. Furlong is the Founding President and CEO of PPMD, the largest nonprofit organization in the U.S. solely focused on Duchenne muscular dystrophy (Duchenne). Their mission is to end Duchenne. They accelerate research, raise their voices in Washington, demand optimal care for all young men, and educate the global community. Duchenne is the most common fatal, genetic childhood disorder, which affects approximately 1 out of every 3,500 boys each year worldwide. It currently has no cure. When doctors diagnosed her two sons, Christopher and Patrick, with Duchenne in 1984, Ms. Furlong didn’t accept “there’s no hope and little help” as an answer. Pat immersed herself in Duchenne, working to understand the pathology of the disorder, the extent of research investment and the mechanisms for optimal care. Her sons lost their battle with Duchenne in their teenage years, but she continues to fight—in their honor and for all families affected by Duchenne. Ms. Furlong sits on CTTI’s Executive Committee.
John Hubbard, Ph.D., FCP  
*Strategic Advisory Board, Genstar Capital*  
Dr. Hubbard was the Chief Executive Officer and President of BioClinica, Inc. from January 5, 2015 to January 1, 2018. He is a leader in the Clinical Services and Biopharmaceutical R&D industries, with over three decades of experience including executive level positions at Pfizer, ICON, Parexel, and Hoechst Marion Roussel Pharmaceuticals. Prior to joining BioClinica, Dr. Hubbard served as Senior Vice President and Worldwide Head of Development Operations for Pfizer Inc. Dr. Hubbard sits on CTTI’s Executive Committee and is the Executive Committee Champion for this MCT Mobile Technologies project.

Leonard Sacks, MD  
*Associate Director for Clinical Methodology, Office of Medical Policy, Center for Drug Evaluation and Research, FDA*  
Dr. Sacks is an Associate Director for Clinical Methodology in the Office of Medical Policy, CDER, FDA, where he has worked on integrating IT opportunities into drug development. He has extensive experience with clinical trials, both as a clinical investigator and subsequently as a reviewer at FDA. He is a clinician, board certified in Internal Medicine and Infectious Diseases. Dr. Sacks initiated the CTTI Mobile in Clinical Trials program and has contributed to all projects within the program.

**A GUIDE TO USING MOBILE TECHNOLOGIES FOR DATA CAPTURE**

- [Executive Summary](#)
- [Glossary: Definition Technical & Regulatory Terms](#)

**CTTI’S JULY 16 MOBILE TECHNOLOGIES EVENT**

- Access the [recommendations and resources](#) (zip file)
- Download the [presentation](#)
- View related [July 16 event materials](#)